AbbVie
ABBV
#36
Rank
NZ$673.82 B
Marketcap
NZ$381.38
Share price
0.40%
Change (1 day)
21.92%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.53. In 2025 the company made an earnings per share (EPS) of NZ$4.10 a decrease over its 2024 EPS that were of NZ$4.15.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-14.4%
2025NZ$4.10-1.26%
2024NZ$4.15-11.86%
2023NZ$4.71-58.95%
2022NZ$11.482.49%
2021NZ$11.20121.58%
2020NZ$5.05-44.7%
2019NZ$9.1445.84%
2018NZ$6.279.72%
2017NZ$5.71-9.54%
2016NZ$6.3116.28%
2015NZ$5.43184.1%
2014NZ$1.91-57.15%
2013NZ$4.46

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.25-36.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.39 1,272.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.82 604.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$16.03 354.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$11.74 233.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.10 73.12%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$11.91 237.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.66 88.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.50 226.30%๐Ÿ‡บ๐Ÿ‡ธ USA